🇺🇸 Keishibukuryogan in United States
42 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 42
Most-reported reactions
- Nausea — 6 reports (14.29%)
- Headache — 5 reports (11.9%)
- Nasopharyngitis — 5 reports (11.9%)
- Constipation — 4 reports (9.52%)
- Diarrhoea — 4 reports (9.52%)
- Dyspnoea — 4 reports (9.52%)
- Malaise — 4 reports (9.52%)
- Vomiting — 4 reports (9.52%)
- Angina Pectoris — 3 reports (7.14%)
- Arthralgia — 3 reports (7.14%)
Other Other approved in United States
Frequently asked questions
Is Keishibukuryogan approved in United States?
Keishibukuryogan does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Keishibukuryogan in United States?
Timothy Welty, PharmD is the originator. The local marketing authorisation holder may differ — check the official source linked above.